{"id":"usel-leucovorin","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1201138","moleculeType":"Small molecule","molecularWeight":"511.51"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting dihydrofolate reductase, leucovorin reduces the levels of tetrahydrofolate, a necessary cofactor for thymidylate synthase. This action is particularly important in cancer treatment, as it allows for the increased efficacy of 5-fluorouracil, a chemotherapeutic agent that also targets thymidylate synthase.","oneSentence":"Leucovorin is a folate analog that inhibits the enzyme dihydrofolate reductase, which is involved in DNA synthesis and repair.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:28.683Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rescue after high-dose methotrexate therapy"},{"name":"Dihydropyrimidine dehydrogenase deficiency"}]},"trialDetails":[{"nctId":"NCT00209742","phase":"PHASE3","title":"Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer","status":"UNKNOWN","sponsor":"Hokkaido Gastrointestinal Cancer Study Group","startDate":"2005-04","conditions":"Colorectal Cancer","enrollment":340}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Leucovorin"],"phase":"phase_3","status":"active","brandName":"USEL/Leucovorin","genericName":"USEL/Leucovorin","companyName":"Hokkaido Gastrointestinal Cancer Study Group","companyId":"hokkaido-gastrointestinal-cancer-study-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"USEL/Leucovorin is a small molecule used in cancer treatment, specifically studied in the context of colorectal cancer. It is used in combination with UFT as an intervention in clinical trials for stage III colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}